Neurosense Therapeutics (NRSN) Key Ratios
$0.51
$0.11
(27.19%)
As on 04-Sep-2026 16:28EDT
Market cap
$16 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 0.00 | -80.49 | -43.42 | 4.10 | -213.67 |
| Net Profit | 0.00 | -78.12 | -8.96 | 2.85 | -214.10 |
| EPS | 0.00 | -61.88 | 25.30 | 16.77 | 2.71 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-25 | Dec-24 | Dec-23 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -1,725.60 | -1,085.84 | -2,174.98 | -2,478.16 | -523.68 |
| Return on Capital
| -1,400.89 | -884.22 | -1,757.50 | -1,965.35 | -479.80 |
| Return on Assets
| -281.93 | -208.18 | -397.11 | -263.14 | -185.53 |
| Debt to Equity (x)
| -- | -- | -0.11 | 0.03 | -0.08 |
Profitability
ROCE
-1,757.50
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-1,757.50
|
-1,965.35
|
-479.80
|
-148.10
|
-70.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-2,174.98
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-2,174.98
|
-2,478.16
|
-523.68
|
-168.75
|
-83.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-397.11
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-397.11
|
-263.14
|
-185.53
|
-128.94
|
-66.19
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-12.39
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-12.39
|
-2.48
|
21.59
|
-326.67
|
-2.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-8.96
--
Year on year growth in profit after tax
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-8.96
|
-1.02
|
18.10
|
-205.37
|
-42.89
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.01
--
Year on year growth in earnings per share
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
0.01
|
0.33
|
0.37
|
-1.84
|
0.27
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.11
--
Total debt / Net worth
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-0.11
|
0.03
|
-0.08
|
0.04
|
0.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.06
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-0.06
|
0.03
|
-0.04
|
0.01
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.31
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
0.31
|
2.21
|
0.84
|
4.28
|
19.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
--
|
--
|
--
|
6.41
|
19.41
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
--
|
-31.83
|
-17.56
|
-821.20
|
-2.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
--
|
--
|
-13,849.38
|
-7,912.38
|
-10,839.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
--
|
21,740.68
|
3,684.51
|
1,101.91
|
5,722.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-1.77
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-1.77
|
-2.73
|
-1.19
|
-1.16
|
-6.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
-12.60
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-12.60
|
10.79
|
-6.86
|
2.56
|
2.99
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-1.77
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Neurosense Therapeutics (NRSN)
|
-1.77
|
-2.49
|
-0.99
|
-0.61
|
-6.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
